

EANM Focus meeting 5: Molecular Imaging and Theranostics in prostate cancer - the future begins today

L.W. van Golen, MD, PhD¹; M.L. Donswijk, MD¹; Prof. M.G.E.H. Lam, MD, PhD²;
Prof. R.A.J.O. Dierckx, MD, PhD³; D.E. Oprea Lager, MD, PhD⁴

¹Antoni van Leeuwenhoek Amsterdam, ²Universitair Medisch Centrum Utrecht, ³Universitair Medisch Centrum Groningen, ⁴Universitair Medisch Centrum Amsterdam.

General

The EANM Focus meeting 5 on (molecular) imaging and (radionuclide) therapy for prostate carcinoma was held 2-4 February 2023 in Sevilla, Spain. The two chairs of this European event were Dutch nuclear medicine physicians: Rudi Dierckx (UMC Groningen; current EANM president) and Daniela Oprea-Lager (Amsterdam UMC; member of EANM Oncology and Theranostics committee). In addition, Dutch faculty included Igle de Jong (UMCG), Sandra Heskamp (Radboud MC), Marnix Lam

(UMCU) and Derya Yakar (UMCG/AVL). The meeting was attended by 300 participants from 34 different countries, covering four continents (i.e., Europe, North America, Africa and Australia).

Overview

EANM focus meetings are meant to provide guidance on nuclear medicine topics, where evidence is weak or lacking. They are based on overview presentations, live interactions of participants and consensus debates with panel experts and faculty

members.

Prior to the Focus 5 meeting, an international multidisciplinary team of experts in prostate cancer, consisting of 29 specialists, had received thematic topics and relevant literature. The experts, who also completed two rounds of a modified e-Delphi questionnaire, were represented by medical oncologists, radiation oncologists, urologists, radiologists, (pre)clinical scientists and nuclear medicine physicians. State-of-the-art theranostic approaches in hormone naive,



Participants from the Netherlands at the EANM Focus Meeting, Sevilla 2023.

hormone sensitive and castration resistant prostate cancer were presented. Internationally recognised expert speakers like Oliver Sartor (New Orleans US, ALSYMPCA and VISION trials), Louise Emmett (Sydney Australia, TheraP and LUPIN trials), Karim Fizazi (Paris Saclay in Villejuif France, Latitude, ARAMIS, PEACE-1 trials) and Bertrand Tombal (UC Louvain Belgium, STOPCAP, PREVAIL trials) gave inspiring presentations. Lectures were followed by plenary discussions and consensus sessions. Statements on different aspects of prostate theranostics were developed. Faculty voted anonymously on a nine-point scale and median scores described agreement and consensus. Statements that had not reached consensus were presented during the meeting and were open to debate. A consensus article, including all topics

discussed, is currently in preparation, to guide practice and assist all colleagues working in the field. The meeting has been accredited by the EACCME® with 15 European CME credits.

Evaluation

The Transavia airlines 7AM Wednesday 1st of February flight delivered 90% of all Dutch nuclear medicine physicians and returned them home Saturday noon, after excellent presentations by Sandra Heskamp and Marnix Lam, but just before an exciting presentation by Louise Emmett. She showed data on [¹⁷⁷Lu]Lu-PSMA therapy and how to use PSMA PET/CT, FDG PET/CT and post-therapy SPECT/CT scans. Ten Australian centers worked together to collect a treasure of data - Emmett was congratulated for setting the example for the rest of the world to follow.

The meeting held in the wonderful environment of sunny Seville closed with a delicious farewell lunch. The only critical comment that could be made is that the multidisciplinary aspect was suboptimal - 70% of participants being nuclear medicine physicians. So next time, EANM is aiming to highly promote the event and to invite a joint committee including other medical societies and colleagues from the tumor board to actively participate in this meeting, as a multidisciplinary team.

Conclusion

Prostate cancer theranostics is one of the most dynamic fields of medicine, requiring a multidisciplinary effort, for the benefit of our patients. Be aware, the future has begun!

la.v.golen@nki.nl ♦

